ÂÜÀòÂÒÂ×

Robert Doody is an accomplished professional specializing in investor relations, currently serving as Senior Vice President of Investor Relations at Prelude Therapeutics since April 2024. Previously, Doody held senior roles at Aclaris Therapeutics, Inc., including the position of Senior Vice President of Investor Relations and a member of the Executive Leadership Team. Other notable roles include Vice President of Investor Relations at Provention Bio, strategic consultant and Senior Vice President at Idera Pharmaceuticals, and Head of Investor Relations at ViroPharma Incorporated, where a significant restructuring of the investor relations approach was executed. Earlier in the career, Doody played a pivotal role in the integration of Shire Pharmaceuticals and held various positions at Dorland Sweeney Jones and the United States Navy. Doody earned a Bachelor of Arts in Communications from Rowan University.